Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 1/2 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Glioblastoma 2Meningeal Carcinomatosis 1Glioma 1

Interventions

Temozolomide 24Radiotherapy 10Magnetic Resonance Spectroscopy 10Radiation 8Specimen Handling 7Lomustine 5Bevacizumab 4Nivolumab 3Biopsy 3Aminolevulinic Acid 3veliparib 2trametinib 2olaparib 2lutetium Lu 177 dotatate 2dabrafenib 2cemiplimab 2azeliragon 2Surgical Procedures, Operative 2Receptors, Interleukin-8B 2Photons 2Palliative Care 2Ipilimumab 2D2C7-(scdsFv)-PE38KDEL 2Carboplatin 2CTLA-4 Antigen 2vocimagene amiretrorepvec 1varlilumab 1ulixertinib 1tinostamustine 1temsirolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Glioblastoma × azeliragon × 30 days × Clear all
NCT05635734 2026-05-29

Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma

Cantex Pharmaceuticals

Phase 1/2 Completed
33 enrolled
CNS

Glioblastoma

NCT06831526 2026-05-29

Neoadjuvant Chemoradiotherapy With or Without Concurrent Azeliragon in Patients With Newly Diagnosed Glioblastoma

Washington University School of Medicine

Phase EARLY_PHASE1 Recruiting
12 enrolled
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡